Accuray Logo
US0043971052
A0MKWM
ARAY

Accuray

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è +1,72 (+647,83%). La mediana è +1,72 (+647,83%).

Acquista
  8
Mantieni
  4
Vendi
  1

  • Accuray reports mixed Q4 results: revenue weaker, stock under pressure

    Accuray slightly beat adjusted loss guidance with EPS of -$0.02 in Q4 but missed revenue estimates with $100.91 million (‑21% year over year). Product revenue plunged 42% in the quarter, while the service business grew 6% and gross margin improved to 34.8%. Management declined to give formal guidance for 2027 due to geopolitical and tariff-related uncertainties, but announced cost cuts, service growth initiatives and a debt-conversion transaction. The stock fell sharply after the results, and the company’s market position remains weighed down by high debt and persistently weak device sales. » Altro su de.investing.com


  • Accuray withdraws full-year guidance after weak quarter and cites geopolitical turbulence

    Accuray reported Q3 revenue of $104.8 million (-7%), missed expectations, and recorded adjusted EBITDA of $3.8 million with a GAAP net loss of $11.8 million. The stock fell in after-hours trading and is trading near its 52-week low. Management cites conflicts in the Middle East, uncertainties in China and tariff debates as reasons and has withdrawn the 2026 full-year guidance. The company meanwhile emphasizes ongoing transformation measures with already realized margin improvements and expects further cost improvements for 2027. » Altro su de.investing.com


  • Accuray adjusts advisory agreement and cuts cash compensation by 50% to reduce costs

    Accuray amended the advisory agreement with Dedication Capital (connected to director Steven F. Mayer): cash fees and minimum premiums for certain periods were reduced by 50%, expected to save at least $362,500. Time-based vesting conditions for 916,336 restricted shares and all performance share awards were deemed satisfied as of April 1; 333,004 remaining shares are scheduled to be issued on October 31, 2026, and the agreement’s termination date was extended to October 31, 2026. The adjustment comes against the backdrop of high debt of $174 million and a market capitalization of $49.75 million; the stock lost 73% in six months but recently gained about 8%. Additionally, Accuray reported Q2 revenue of $102.2 million (below expectations) with EPS of -$0.11, BTIG cut its price target from $4 to $2, and NASDAQ flagged ongoing minimum-price violations. » Altro su de.investing.com

Nel 2022, Accuray ha già distribuito +0,62 di dividendi. L'ultimo pagamento è avvenuto a giugno 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Accuray ha registrato ricavi pari a +88,43M e un utile netto di 1,70M
(EUR) giu 2026
YoY
Ricavi +88,43M 18,28%
Utile lordo +31,14M 5,84%
Utile netto 1,70M 278,50%
EBITDA +62,21k 99,07%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
+27,74M
Numero di azioni
118,96M
Massimo/minimo a 52 settimane
+1,80 - +0,19
Dividendi No
Beta
1,39
Rapporto P/E
0,69
Rapporto PEG
0,00
Rapporto P/B
+0,80
Rapporto P/S
+0,08

Profilo aziendale

Accuray Incorporated entwirft, entwickelt, produziert und vertreibt Radiochirurgie- und Strahlentherapiesysteme für die Behandlung von Tumoren in Nord- und Südamerika, Europa, dem Nahen Osten, Indien, Afrika, Japan, China und dem restlichen asiatisch-pazifischen Raum. Das Unternehmen bietet das CyberKnife System an, ein robotergestütztes stereotaktisches Radiochirurgie- und stereotaktisches Strahlentherapiesystem, das für die Behandlung verschiedener Krebsarten und Tumore im Körper eingesetzt wird, z. B. Prostata, Lunge, Gehirn, Wirbelsäule, Leber, Bauchspeicheldrüse und Niere. Das Unternehmen bietet auch das TomoTherapy-System an, einschließlich des Radixact-Systems, das aus einem integrierten Strahlentherapiesystem besteht, das für die Behandlung einer Reihe von Krebsarten entwickelt wurde. Darüber hinaus bietet es Kundendienst, Installation, Schulung und andere professionelle Dienstleistungen nach Vertragsabschluss an. Das Unternehmen vertreibt seine Produkte in erster Linie direkt an Kunden, darunter Krankenhäuser und eigenständige Behandlungseinrichtungen, über seine Vertriebsorganisation sowie an Kunden über Handelsvertreter und Einkaufsgemeinschaften in den Vereinigten Staaten und an Kunden direkt und über Vertriebshändler und Handelsvertreter international. Accuray Incorporated wurde 1990 gegründet und hat seinen Hauptsitz in Sunnyvale, Kalifornien.

Nome
Accuray
CEO
Stephen R. LaNeve
Sede centrale Madison, wi
Stati Uniti
Sito web
Settore
Beni voluttuari
Industria
Beni durevoli per la casa
Quotazione in borsa
08/02/2007
Dipendenti 990

Simboli di borsa

Borsa Simbolo
NASDAQ
ARAY
London Stock Exchange
0H8I.L
Frankfurt
XEJ.F
Düsseldorf
XEJ.DU
London
0H8I.L
SIX
XEJ.SW
München
XEJ.MU
🍪

Parqet  usa i cookie. Scopri di più